{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:08:52Z","timestamp":1788404932949,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.06.017","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:32:33Z","timestamp":1781105553000},"page":"5175-5189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4854-5221","authenticated-orcid":false,"given":"Alexander","family":"Kinna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeta","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyisa","family":"Bughda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhaan","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hogben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Weng-Kit Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Hazelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulaikha","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Macken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofi","family":"Panovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Kholy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reevesh","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Kokalaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sillibourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimobi","family":"Onuoha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.06.017_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.06.017_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V128.22.379.379","article-title":"An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in vitro and in vivo","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.017_bib3","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13R\u03b12-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.06.017_bib4","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","article-title":"Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain","volume":"21","author":"Buonato","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2026.06.017_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.06.017_bib6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.017_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/374168a0","article-title":"A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks","volume":"374","author":"Greenberg","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.017_bib8","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1073\/pnas.95.20.11804","article-title":"Structural analysis of the nurse shark (new) antigen receptor (NAR): Molecular convergence of NAR and unusual mammalian immunoglobulins","volume":"95","author":"Roux","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.017_bib9","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.06.017_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s43018-022-00344-7","article-title":"Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues","volume":"3","author":"Feng","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.06.017_bib11","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2021.39.15_suppl.8005","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): Updated results from CARTITUDE-1","volume":"39","author":"Usmani","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.ymthe.2026.06.017_bib12","first-page":"450","article-title":"Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells","volume":"21","author":"Wang","year":"2021","journal-title":"Cancer Cel Int."},{"key":"10.1016\/j.ymthe.2026.06.017_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40364-021-00332-6","article-title":"A comprehensive comparison between camelid nanobodies and single chain variable fragments","volume":"9","author":"Asaadi","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ymthe.2026.06.017_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1864084","article-title":"Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments","volume":"13","author":"Nannini","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.06.017_bib15","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1093\/bioinformatics\/btab434","article-title":"Humanization of antibodies using a machine learning approach on large-scale repertoire data","volume":"37","author":"Marks","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.06.017_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.2020203","article-title":"BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning","volume":"14","author":"Prihoda","year":"2022","journal-title":"mAbs"},{"key":"10.1016\/j.ymthe.2026.06.017_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2026.06.017_bib18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.017_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.08.010","article-title":"Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents","volume":"334","author":"Sharifzadeh","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2026.06.017_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J. Nanobiotechnol"},{"key":"10.1016\/j.ymthe.2026.06.017_bib21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ymthe.2026.06.017_bib22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4161\/mabs.24218","article-title":"A fully synthetic human Fab antibody library based on fixed VH\/VL framework pairings with favorable biophysical properties","volume":"5","author":"Tiller","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.06.017_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.885672","article-title":"Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients","volume":"13","author":"Mosch","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.017_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity Risk Profile of Nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.017_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1063838","article-title":"T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts","volume":"14","author":"Nasiri","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.017_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002173","article-title":"Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors","volume":"9","author":"Wang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.06.017_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00262-023-03602-4","article-title":"New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo","volume":"73","author":"Jancewicz","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2026.06.017_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12896-023-00827-0","article-title":"Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell","volume":"24","author":"Taheri","year":"2024","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.ymthe.2026.06.017_bib29","article-title":"Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.017_bib30","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.017_bib31","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1021\/acs.molpharmaceut.8b00584","article-title":"Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells","volume":"15","author":"An","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2026.06.017_bib32","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","article-title":"Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.017_bib33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/ijms21030883","article-title":"Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly","volume":"21","author":"De Munter","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.06.017_bib34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.017_bib35","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1038\/ncomms6479","article-title":"The immune synapse clears and excludes molecules above a size threshold","volume":"5","author":"Cartwright","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.017_bib36","doi-asserted-by":"crossref","first-page":"366ra162","DOI":"10.1126\/scitranslmed.aaf8463","article-title":"Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation","volume":"8","author":"Danquah","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.017_bib37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/19420862.2018.1489633","article-title":"Antigen recognition by single-domain antibodies: structural latitudes and constraints","volume":"10","author":"Henry","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.ymthe.2026.06.017_bib38","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ymthe.2018.01.020","article-title":"Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells","volume":"26","author":"Xiong","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.017_bib39","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2026.06.017_bib40","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.1038\/s41467-025-61427-4","article-title":"Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function","volume":"16","author":"Barisa","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.017_bib41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12943-023-01886-9","article-title":"Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2026.06.017_bib42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jcyt.2017.03.067","article-title":"Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion","volume":"19","author":"Kaartinen","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.06.017_bib43","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1086\/591250","article-title":"CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients","volume":"198","author":"Read","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.06.017_bib44","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2003-12-4355","article-title":"IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation","volume":"104","author":"Sereti","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.017_bib45","doi-asserted-by":"crossref","first-page":"D1368","DOI":"10.1093\/nar\/gkab1050","article-title":"SAbDab in the age of biotherapeutics: updates including SAbDab-nano, the nanobody structure tracker","volume":"50","author":"Schneider","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.06.017_bib46","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41467-024-45854-3","article-title":"Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies","volume":"15","author":"Ferrari","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:18:13Z","timestamp":1788362293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626004946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525001626004946"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}